免疫检查点抑制剂新辅助治疗肌层浸润性膀胱癌的系统评价与网络Meta分析
该系统评价与网络Meta分析纳入12项RCT(5004例)和35项非RCT(2964例),评估新辅助免疫检查点抑制剂(ICI)方案对肌层浸润性膀胱癌肿瘤学结局的影响。结果显示ICI联合化疗较单纯化疗显著提高病理完全缓解率(40.6% vs 17.9%,p<0.01),但两项3期RCT(1556例)中durvalumab+GC与ddMVAC的总生存无显著差异(HR 1.06,95%CI 0.72-1.55;p=0.8)。
要点
- ICI联合化疗较单纯化疗显著提高pCR率(40.6% vs 17.9%,p<0.01)。
- durvalumab+GC与ddMVAC的总生存无显著差异(HR 1.06,95%CI 0.72-1.55;p=0.8)。
- ddMVAC较GC显著增加≥3级贫血和乏力风险,durvalumab+GC未增加。
核心结论
- 新辅助化疗联合ICI较单纯化疗显著提高pCR率,但durvalumab+GC与ddMVAC的OS无差异,ICI联合方案的OS获益尚需进一步研究。
研究设计与样本
- 系统检索MEDLINE、Embase、Web of Science和ClinicalTrials.gov(2024年9月),纳入12项RCT(5004例)和35项非RCT(2964例),采用随机效应模型进行比例Meta分析和网络Meta分析,注册于PROSPERO(CRD42024587964)。
主要发现
- ICI联合化疗较单纯化疗的pCR率为40.6% vs 17.9%(p<0.01)。
- 两项3期RCT(1556例)中,durvalumab+GC与ddMVAC的OS无显著差异(HR 1.06,95%CI 0.72-1.55;p=0.8)。
- ddMVAC较GC显著增加≥3级贫血(RR 2.81,95%CI 1.62-4.88)和乏力(RR 3.46,95%CI 1.68-7.14)风险,durvalumab+GC未增加。
关键数值与推荐
- ICI联合化疗较单纯化疗显著提高pCR率(40.6% vs 17.9%;p<0.01)。
- durvalumab+GC与ddMVAC的OS无显著差异(HR 1.06,95%CI 0.72-1.55;p=0.8)。
- ddMVAC较GC显著增加≥3级贫血(RR 2.81,95%CI 1.62-4.88)和乏力(RR 3.46,95%CI 1.68-7.14)风险。
临床怎么用
- 新辅助ICI联合化疗可提高pCR率,但需权衡OS获益尚不明确及毒性风险。
- ddMVAC的≥3级贫血和乏力风险较高,durvalumab+GC未增加这些风险。
局限性
- 研究间数据异质性较大。
- 网络Meta分析纳入的研究数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The availability of immune checkpoint inhibitors (ICIs) has expanded perioperative treatment options for urothelial carcinoma. Our aim was to evaluate the effect of neoadjuvant ICI-based regimens on oncological outcomes for patients with muscle-invasive bladder cancer (MIBC). METHODS: We systematically searched MEDLINE, Embase, Web of Science, and ClinicalTrials.gov in September 2024 for studies on neoadjuvant therapies for MIBC. A proportion meta-analysis and network meta-analysis (NMA) using random-effect models were conducted to evaluate pooled pathological complete response (pCR) rates and to compare overall survival (OS) and adverse events. The review is registered on PROSPERO (CRD42024587964). KEY FINDINGS AND LIMITATIONS: We included 12 randomized controlled trials (RCTs; 5004 patients) and 35 non-RCTs (2964 patients). ICI-chemotherapy combination therapy was associated with a significantly higher pCR rate versus chemotherapy alone (40.6% vs 17.9%; p < 0.01). In the two phase 3 RCTs included (1556 patients) there was no significant difference in OS between dose-dense methotrexate + vinblastine + Adriamycin + cisplatin (ddMVAC) and durvalumab + gemcitabine + cisplatin (GC; hazard ratio 1.06, 95% confidence interval [CI] 0.72-1.55; p = 0.8). ddMVAC significantly increased the risk of grade ≥3 anemia (risk ratio [RR] 2.81, 95% CI 1.62-4.88) and asthenia (RR 3.46, 95% CI 1.68-7.14) in comparison to GC, while durvalumab + GC did not. Limitations include data heterogeneity across studies and the limited number of studies included in the NMA. CONCLUSIONS AND CLINICAL IMPLICATIONS: ICI addition to chemotherapy in the neoadjuvant MIBC setting significantly increased pCR rates in comparison to chemotherapy alone. However, there was no difference in OS between durvalumab + GC and ddMVAC. Further studies are needed to clarify the OS benefit of ICI-based combination therapy in comparison to the current standard chemotherapy regimen.
引用
- Matsukawa A, Cormio A, Miszczyk M, et al. Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis. Eur Urol Oncol. 2025. PMID: 40288918. doi:10.1016/j.euo.2025.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。